Home Sectors Healthcare Love or Hate: Eagle Pharmaceuticals (NASDAQ: EGRX)

Love or Hate: Eagle Pharmaceuticals (NASDAQ: EGRX)

SHARE

Eagle Pharmaceuticals is in the healthcare sector and is part of the drug manufacturers industry. The company CEO is Scott L. Tarriff. Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology.

Previous Intraday Trading Performance:

The EGRX stock showed a previous change of 0.15% with an open at 48.20 and a close of 48.21. It reached an intraday high of 48.62 and a low of 47.70.

SeekingAlpha:  Eagle Pharmaceuticals’ (EGRX) CEO Scott Tarriff on Q4 2018 Results – Earnings Call Transcript

Liquidity:

The stock has a market cap of $671.3m with 13.9m shares outstanding, of which the float is 12.2m shares. Trading volume reached 110,714 shares compared to its average volume of 212,471 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Eagle Pharmaceuticals shares returned 1.35% and in the past 30 trading days it returned 15.61%. Over three months, it changed 9.34%. In one year it has changed -17.38% and within that year its 52-week high was 85.66 and its 52-week low was 36.03. EGRX stock is 33.80% above its 52 Week Low.

Our calculations show a 200 day moving average of 59.92 and a 50 day moving average of 43.39. Currently EGRX stock is trading -19.55% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Eagle Pharmaceuticals beats by $0.04, beats on revenue

Earnings:

The last annual fiscal EPS for the company was reported at 2.11 that ended on 31st of December 2018, which according to the previous close, that is a PE of 23.07. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.79. The TTM EPS is 2.11, which comes to a TTM PE of 22.85.

The following are the last four quarter reported earnings per share:
12-31-2018:  0.86
09-30-2018:  0.91
06-30-2018:  0.17
03-31-2018:  0.17

Base on our calculations, the intrinsic value per share is 60.78, which means it is possibly undervalued and has a margin of safety of 20.69%

Indicators to Watch:

Based on the latest filings, there is 147.40% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.69

Business Wire:  Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 19.20%, return on assets is 12.84%, profit margin is 15.22%, price-to-sales is 3.14 and price-to-book is 4.17.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 3  :Past Performance Score
 5  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.